<section class="Section" data-sectioncode="34089-3"><a name="LINK_7ed0975d-d0c2-465e-aeef-d5e55e935595"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Eptinezumab-jjmr is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Eptinezumab-jjmr has an approximate molecular weight of 143 kD. Eptinezumab-jjmr is produced in <span class="Italics">Pichia pastoris</span> yeast cells by recombinant DNA technology. </p><p>VYEPTI (eptinezumab-jjmr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to brownish-yellow solution, for intravenous infusion. VYEPTI is supplied as a 100 mg/mL single-dose vial. Each mL contains 100 mg eptinezumab-jjmr formulated in L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.</p></section>

Vyepti

1 ML eptinezumab-jjmr 100 MG/ML Injection

1 ML eptinezumab-jjmr 100 MG/ML Injection [Vyepti]

eptinezumab

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa.</p><p>AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous administration. Each 1 mL 70 mg single-dose prefilled autoinjector and 70 mg single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg), and sucrose (73 mg). Each 1 mL 140 mg single-dose prefilled autoinjector and 140 mg single-dose prefilled glass syringe contains 140 mg erenumab-aooe, acetate (2.0 mg), polysorbate 80 (0.10 mg), and sucrose (65 mg). Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of AIMOVIG has a pH of 5.2.</p></section>

AIMOVIG

1 ML erenumab-aooe 140 MG/ML Auto-Injector

1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimovig]

1 ML erenumab-aooe 140 MG/ML Prefilled Syringe

1 ML erenumab-aooe 140 MG/ML Prefilled Syringe [Aimovig]

1 ML erenumab-aooe 70 MG/ML Auto-Injector

1 ML erenumab-aooe 70 MG/ML Auto-Injector [Aimovig]

1 ML erenumab-aooe 70 MG/ML Prefilled Syringe

1 ML erenumab-aooe 70 MG/ML Prefilled Syringe [Aimovig]

Aimovig

erenumab

Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were stuffy nose and scratchy throat. 

Vyepti is FDA approved for the following indications: Migraine prevention. 


Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request

Pharmacy List 

Reimbursement Information 

How To Order Vyepti

Billing and Coding Guide

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity

Letter of Medical Exception

Vyepti Connect Enrollment Form

Enroll in Patient Savings Program

Vyepti Infusion Locator 

Mechanism of Action (MOA)

Clinical Trial: Episodic Migraine 

Efficacy: Episodic Migraine 

Clinical Trial: Chronic Migraine 

Efficacy: Chronic Migraine 

Safety Profile

Dosing & Administration

Other HCP Resources: Access

Other HCP Resources 

About Vyepti

Side Effects 

What to Expect During Treatment

Patient Stories 

Patient Resources 

Nurse Support 

FAQs: Migraine

Instructions For Use (Home Infusion): Migraine 

Patient Brochure 

Doctor Discussion Guide 

Appointment Reminder

Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site reactions and constipation. However, there are no reported instances of drug interactions with Aimovig.

Aimovig is FDA approved for the following indications: Migraine prevention. 


Report Adverse Event 

Prescribing Information - Spanish

Medication Guide: Latex containing Pen 

Medication Guide: Non-Latex Pen 

Submit MSL Request 

Online Sample Form [Connect With A Rep Pop-Up]

Letter of Medical Necessity 

PA Checklist 

Enroll in Patient Savings Program 

Amgen Safety Net Foundation Eligibility Check 

Efficacy (vs Topiramate)

Efficacy (Pivotal & Long-Term)

Efficacy (Chronic Migraine)

Safety Profile (vs Topiramate)

Safety Profile (Pivotal & Long-Term)

Dosing 

About Aimovig 

Taking Aimovig

Side Effects

AimAlly Support Program 

Aimovig Start Guide 

Instructions For Use (Video): Migraine Prevention 

Instructions For Use [Prefilled SureClick Autoinjector 70mg/ml]: Migraine Prevention 

Instructions For Use [Prefilled SureClick Autoinjector 140 mg/mL]: Migraine Prevention 

Vyepti®(eptinezumab)	Aimovig®(erenumab)

Prescription Only Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...	Prescription Only Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...
Dosage & Administration
Administration
Intravenous infusion (must be diluted). Learn more.	Subcutaneous . Learn more.
Dosing
100 mg every 3 months or 300 mg (for some patients). Learn more.	70 mg once monthly or 140 mg once monthly (for some patients). Learn more.
Latin Shorthand
100 mg q3mo. Learn more.	70 mg/mo or 140 mg/mo. Learn more.
Adverse Reactions
The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.	The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$5. Learn more.
Annual Cap
$200 per infusion for administration costs. Learn more.	Patient specific maximum benefit.. Learn more.
Assistance Expiration
Calendar year. Learn more.	Calendar year. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available

Vyepti® Alternatives